文献速递自身炎症与 IgG4 相关病

IgG4相关疾病应答指数国际多专科验证研究

An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-01-01

该研究旨在多国多专科验证IgG4相关疾病应答指数(RI),26名医师来自6个专科9个国家,先对12份真实患者书面病例计算RI与医师整体评估(PhGA),再由3名医师对15例新发活动期患者纵向随访评估。结果显示RI评分者间信度0.89、评分者内信度0.69,RI与PhGA相关系数r=0.9(P<0.0001),治疗后RI平均变化10.5(95%CI 5.4-12,P<0.001)。

要点

  • RI评分者间信度0.89、评分者内信度0.69,与PhGA相关系数r=0.9(P<0.0001)。
  • RI可敏感反映治疗前后变化,治疗后RI平均变化10.5(95%CI 5.4-12,P<0.001)。
  • RI可有效捕捉需紧急治疗的病变及器官损伤。

核心结论

  • 在这项国际多专科研究中,RI是有效且可靠的疾病活动度评估工具,可用于测量治疗反应。

研究设计与样本

  • 国际多专科验证研究,26名医师研究者来自6个专科、9个国家。
  • 先经培训后由研究者审阅12份基于真实患者的书面IgG4相关疾病病例,计算RI评分与PhGA评分。
  • 纵向评估中3名研究者对15例新发活动期患者使用RI,并在治疗后多次随访。
  • 评估指标包括评分者间与评分者内信度、精确度、效度与反应度。

主要发现

  • RI评分者间信度为0.89,评分者内信度为0.69。
  • RI与PhGA的相关系数(结构效度)为Spearman r=0.9(P<0.0001)。
  • RI对变化敏感(区分效度)。
  • 治疗后RI评分显著改善,平均变化10.5(95%CI 5.4-12,P<0.001),且与PhGA变化相关。
  • 紧急病变与损伤被有效捕捉。

关键数值与推荐

  • RI通过25个领域的疾病活动度与损伤评估指导研究者,对需紧急治疗或治疗后仍加重的表现赋予更高权重。

临床怎么用

  • 作者认为RI是有效且可靠的疾病活动度评估工具,可用于测量治疗反应。

局限性

  • 摘要未报告局限性,原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. METHODS: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. RESULTS: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4-12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. DISCUSSION: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wallace ZS, Khosroshahi A, Carruthers MD, et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care Res (Hoboken). 2018. PMID: 29457382. doi:10.1002/acr.23543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。